The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma - Full Text View

The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

This study is ongoing, but not recruiting participants.

Sponsored by:	Rambam Health Care Campus
Information provided by:	Rambam Health Care Campus
ClinicalTrials.gov Identifier:	NCT00498667

Purpose

A retrospective analysis will be performed regarding the usefullness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with agressive non Hodgkin Lymphoma.

Condition

Agressive B Cells Lymphoma

MedlinePlus related topics:

Lymphoma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study

Official Title:	Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment:	150
Study Start Date:	December 2006
Estimated Study Completion Date:	December 2009

Detailed Description:

Patients who were treated for agressive non Hodgkin lymphoma with adriamicin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

agressive non hodgkin lymphoma b cells
age 18-70
bilirubin less then 2
creatinine less then 2
Pet/CT performed post 2 cycles

Exclusion Criteria:

no PET/CT post 2 cycles performed
bilirubin >2
creatinin more then 2
HIV positivity

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00498667

Locations


Israel
	RAMBAM health care Campus
	Haifa, Israel, 31096

Sponsors and Collaborators

Rambam Health Care Campus

Investigators


Principal Investigator:	Eldad J Dann, MD	RAMBAM health care campus,Rappaport faculty of medicine Technion Israel Technical institute

More Information

Study ID Numbers:	cc-NHL2615_CTIL
First Received:	July 8, 2007
Last Updated:	July 8, 2007
ClinicalTrials.gov Identifier:	NCT00498667
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:

PET/CT

Agressive non Hodgkin Lymphoma

Study placed in the following topic categories:

Lymphoma, B-Cell

Lymphatic Diseases

Immunoproliferative Disorders

B-cell lymphomas

Lymphoma, small cleaved-cell, diffuse

Disease Progression

Lymphoproliferative Disorders

Aggression

Lymphoma, Non-Hodgkin

Lymphoma

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Histologic Type

Immune System Diseases

ClinicalTrials.gov processed this record on October 06, 2008